Continuation of Covered Calls Position in Halozyme Therapeutics Inc.

The Covered Calls Advisor Portfolio has a Covered Calls position in Halozyme Therapeutics Inc. (ticker HALO) which expired out-of-the-money at last Friday's options expiration.  Today this position was continued by rolling out to the February 16th, 2024 weekly options expiration at the $35.00 strike price by selling-to-open four Calls at $1.55 per share when the price of Halozyme was $34.83.  The Implied Volatility of the Call options was 40.2 when this transaction was executed.  

As detailed below, a potential outcome for this Halozyme investment is +7.0% absolute return-on-investment over 44 days (equivalent to +57.7% annualized-return-on-investment) if the stock closes above the $35.00 strike price on the February 16th, 2024 options expiration date.  The transactions history of this Halozyme Covered Calls position so far along with a potential return-on-investment result if the stock is assigned on the February 16th, 2024 options expiration date is as follows:

Halozyme Therapeutics Inc. (HALO) -- Continuation of Covered Calls Position

The net debit buy/write limit order was executed as follows:

1/3/2024 Bought 400 shares of Halozyme Therapeutics stock @ $36.32 per share.  
1/3/2024 Sold 4 HALO January 19th, 2024 $35.00 Call options @ $2.16 per share.
1/19/2024 4 HALO $35.00 Call options expired out-of-the-money and 400 Halozyme shares remain in the Covered Calls Advisor Portfolio

1/22/2024 Continued this Halozyme Covered Calls position by selling 4 February 16th, 2024 Call options at $1.55 per share.

Note: The Implied Volatility of the Calls was 40.2 when this position was established.  

A possible overall performance result (including commissions) if this position is assigned on its 2/16/2024 options expiration date is follows:
Halozyme Covered Calls Net Investment: $13,666.68
= ($36.32 - $2.16) * 400 shares + $2.68 commission

Net Profit Components:
(a) Options Income: +$1,478.64
= ($2.16 + $1.55) * 400 shares - $5.36 commissions
(b) Dividend Income: +$0.00
(c) Capital Appreciation (If Halozyme stock is above the $35.00 strike price at the Feb. 16th options expiration date): -$528.00
= ($35.00 - $36.32) * 400 shares

Potential Total Net Profit (If assigned at expiration): +$950.64
= (+$1,478.64 options income + $0.00 dividend income - $528.00 capital appreciation)

Potential Absolute Return-on-Investment: +7.0%
= +$950.64/$13,666.68
Potential Equivalent Annualized-Return-on-Investment: +57.7%
= (+$950.64/$13,666.68) * (365/44 days)